GlassScriptPhysician profile
Rahim M Dhanani
NPI 1346291655
$8,350.43
in general payments reported to CMS, 2019-2025
31 companies · $1,109 in 2025
The $1,109 reported for 2025 was more than what 80% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,202 · 2020: $817 · 2021: $950 · 2022: $1,981 · 2023: $1,331 · 2024: $961 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,322 · Education: $78.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,321.55 |
| Education | $78.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,188.22 | 2019-2025 | Farxiga, Lokelma, Evusheld |
| Merck Sharp & Dohme LLC | $1,003.93 | 2022 | |
| Mallinckrodt Hospital Products INC. | $759.57 | 2020-2025 | Acthar, Terlivaz |
| Otsuka America Pharmaceutical, INC. | $759.15 | 2019-2025 | Jynarque |
| Glaxosmithkline, LLC. | $623.55 | 2020-2025 | Benlysta, Jesduvroq |
| Akebia Therapeutics INC | $443.62 | 2019-2025 | Vafseo, Auryxia |
| Vifor Pharma, INC. | $426.68 | 2019-2025 | Veltassa |
| Opko Pharmaceuticals, LLC | $416.49 | 2019-2024 | Rayaldee |
| Horizon Therapeutics Plc | $303.01 | 2021-2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $276.16 | 2019-2024 | Velphoro |
| Amgen INC. | $240.24 | 2021-2025 | Krystexxa, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $207.61 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $206.50 | 2023-2025 | Tarpeyo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $191.94 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.04 | 2024-2025 | Jardiance |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $183.86 | 2019-2025 | Rivfloza |
| Sanofi-Aventis U.S. LLC | $122.88 | 2022 | |
| Tosoh Bioscience, INC. | $118.24 | 2021 | |
| Lundbeck LLC | $118.18 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $104.26 | 2019-2025 | Ultomiris |
| Nxstage Medical, INC. | $85.29 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $73.36 | 2019-2021 | |
| Travere Therapeutics, INC. | $64.69 | 2020-2025 | |
| Renalytix Ai, INC. | $64.07 | 2022-2023 | Kidneyintelx Blood Collection Convenience Kit |
| Janssen Pharmaceuticals, INC | $62.13 | 2019-2020 | |
| Genzyme Corporation | $36.37 | 2019-2023 | |
| Lilly USA, LLC | $24.55 | 2023 | Jardiance |
| Rhythm Pharmaceuticals, INC. | $19.69 | 2022 | |
| Daiichi Sankyo INC. | $14.87 | 2025 | Injectafer |
| Mallinckrodt Enterprises LLC | $13.12 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahim Dhanani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.